The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients
Open Access
- 1 January 2022
- journal article
- research article
- Published by Taylor & Francis Ltd in Molecular and Cellular Biology
- Vol. 42 (1), e0046721
- https://doi.org/10.1128/mcb.00467-21
Abstract
A subset of hospitalized COVID-19 patients, particularly the aged and those with comorbidities, develop the most severe form of the disease, characterized by acute respiratory disease syndrome (ARDS), coincident with experiencing a "cytokine storm." Here, we demonstrate that cytokines which activate the NF-κB pathway can induce activin A. Patients with elevated activin A, activin B, and FLRG at hospital admission were associated with the most severe outcomes of COVID-19, including the requirement for mechanical ventilation, and all-cause mortality. A prior study showed that activin A could decrease viral load, which indicated there might be a risk to giving COVID-19 patients an inhibitor of activin. To evaluate this, the role for activin A was examined in a hamster model of SARS-CoV-2 infection, via blockade of activin A signaling. The hamster model demonstrated that use of an anti-activin A antibody did not worsen the disease and there was no evidence for increase in lung viral load and pathology. The study indicates blockade of activin signaling may be beneficial in treating COVID-19 patients experiencing ARDS.Keywords
Funding Information
- Regeneron Pharmaceuticals
This publication has 28 references indexed in Scilit:
- Distinct Molecular Phenotypes of Direct vs Indirect ARDS in Single-Center and Multicenter StudiesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2015
- Signaling pathways controlling skeletal muscle massCritical Reviews in Biochemistry and Molecular Biology, 2013
- Cancer Cachexia: Mediators, Signaling, and Metabolic PathwaysCell Metabolism, 2012
- Activin-A Overexpression in the Murine Lung Causes Pathology That Simulates Acute Respiratory Distress SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 2012
- TAK-1/p38/nNFκB signaling inhibits myoblast differentiation by increasing levels of Activin ASkeletal Muscle, 2012
- Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube sizeAmerican Journal of Physiology-Cell Physiology, 2009
- Silencing of FLRG, an Antagonist of Activin, Inhibits Human Breast Tumor Cell GrowthCancer Research, 2007
- Neutrophil apoptosis: a marker of disease severity in sepsis and sepsis-induced acute respiratory distress syndromeCritical Care, 2006
- FLRG, an activin-binding protein, is a new target of TGFβ transcription activation through Smad proteinsOncogene, 2001
- Effects of Activin A on Proliferation and Differentiation of Human Lung FibroblastsBiochemical and Biophysical Research Communications, 1996